Identification

Name
Dutasteride
Accession Number
DB01126  (APRD00385)
Type
Small Molecule
Groups
Approved, Investigational
Description

Dutasteride belongs to a class of drugs called 5-alpha-reductase inhibitors, which block the action of the 5-alpha-reductase enzymes that convert testosterone into dihydrotestosterone (DHT). Finasteride also belongs to this group, but while dutasteride inhibits both isoforms of 5-alpha reductase, finasteride inhibits only one. Even so, a clinical study done by GlaxoSmithKline, the EPICS trial, did not find dutasteride to be more effective than finasteride in treating BPH. [Wikipedia]

Structure
Thumb
Synonyms
  • (5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
  • alpha,alpha,alpha,Alpha',alpha',alpha'-hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide
External IDs
GG-745 / GI 198745 / GI-198745
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act DutasterideCapsule0.5 mgOralTeva2014-09-05Not applicableCanada
AvodartCapsule0.5 mgOralGlaxosmithkline Inc2003-11-14Not applicableCanada
AvodartCapsule, liquid filled0.5 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-03-262016-12-31Us
AvodartCapsule, liquid filled0.5 mg/1OralA-S Medication Solutions2002-12-10Not applicableUs54569 660720180907 15195 z78nd1
AvodartCapsule, liquid filled0.5 mg/1OralPhysicians Total Care, Inc.2004-07-16Not applicableUs54868 511420180907 15195 1wntyr8
AvodartCapsule, liquid filled0.5 mg/1OralAvera McKennan Hospital2015-03-23Not applicableUs69189 071220180907 15195 1tvib44
AvodartCapsule, liquid filled0.5 mg/1OralGlaxosmithkline Inc2002-12-10Not applicableUs00173 0712 02 nlmimage10 32191978
AvodartCapsule, liquid filled0.5 mg/1OralPreferreed Pharmaceuticals Inc.2002-12-102013-11-30Us
DutasterideCapsule0.5 mgOralSivem Pharmaceuticals Ulc2014-10-08Not applicableCanada
DutasterideCapsule0.5 mgOralSanis Health Inc2015-07-21Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-dutasterideCapsule0.5 mgOralApotex Corporation2014-07-18Not applicableCanada
Auro-dutasterideCapsule0.5 mgOralAuro Pharma IncNot applicableNot applicableCanada
DutasterideCapsule0.5 mg/1OralA-S Medication Solutions2015-11-02Not applicableUs
DutasterideCapsule0.5 mg/1OralWest-Ward Pharmaceuticals Corp.2013-08-01Not applicableUs
DutasterideCapsule, liquid filled0.5 mg/1OralZydus Pharmaceuticals Usa, Inc.2018-05-16Not applicableUs
DutasterideCapsule0.5 mg/1OralProficient Rx LP2015-11-20Not applicableUs
DutasterideCapsule, liquid filled0.5 mg/1OralAv Pak2017-11-07Not applicableUs
DutasterideCapsule, liquid filled0.5 mg/1OralA-S Medication Solutions2015-11-25Not applicableUs
DutasterideCapsule, liquid filled0.5 mg/1OralRising Pharmaceuticals2015-11-20Not applicableUs
DutasterideCapsule, liquid filled0.5 mg/1OralNucare Pharmaceuticals,inc.2015-11-25Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Dutasteride and Tamsulosin HydrochlorideDutasteride (0.5 mg/1) + Tamsulosin Hydrochloride (0.4 mg/1)CapsuleOralPar Pharmaceutical2015-11-18Not applicableUs
Dutasteride and tamsulosin hydrochlorideDutasteride (0.5 mg/1) + Tamsulosin Hydrochloride (0.4 mg/1)CapsuleOralZydus Pharmaceuticals Usa, Inc.2018-06-04Not applicableUs
Dutasteride and tamsulosin hydrochlorideDutasteride (0.5 mg/1) + Tamsulosin Hydrochloride (0.4 mg/1)CapsuleOralActavis Pharma Company2016-04-13Not applicableUs
Dutasteride and Tamsulosin HydrochlorideDutasteride (0.5 mg/1) + Tamsulosin Hydrochloride (0.4 mg/1)CapsuleOralPrasco Laboratories2016-07-01Not applicableUs
Dutasteride and tamsulosin hydrochlorideDutasteride (0.5 mg/1) + Tamsulosin Hydrochloride (0.4 mg/1)CapsuleOralCadila Pharnmaceuticals2018-06-04Not applicableUs
JalynDutasteride (0.5 mg) + Tamsulosin Hydrochloride (0.4 mg)Capsule, extended releaseOralGlaxosmithkline Inc2011-11-17Not applicableCanada
JalynDutasteride (0.5 mg/1) + Tamsulosin Hydrochloride (0.4 mg/1)CapsuleOralPhysicians Total Care, Inc.2012-05-02Not applicableUs54868 632820180907 15195 11okuzb
JalynDutasteride (0.5 mg/1) + Tamsulosin Hydrochloride (0.4 mg/1)CapsuleOralGlaxoSmithKline LLC2010-06-21Not applicableUs00173 0809 61 nlmimage10 d11968cb
Categories
UNII
O0J6XJN02I
CAS number
164656-23-9
Weight
Average: 528.5297
Monoisotopic: 528.221147444
Chemical Formula
C27H30F6N2O2
InChI Key
JWJOTENAMICLJG-QWBYCMEYSA-N
InChI
InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1
IUPAC Name
(1S,2R,7R,10S,11S,14S,15S)-N-[2,5-bis(trifluoromethyl)phenyl]-2,15-dimethyl-5-oxo-6-azatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-3-ene-14-carboxamide
SMILES
[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])NC(=O)C=C[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)NC1=CC(=CC=C1C(F)(F)F)C(F)(F)F

Pharmacology

Indication

For the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland to improve symptoms, and reduce the risk of acute urinary retention and the need for surgery.

Associated Conditions
Pharmacodynamics

Dutasteride is a synthetic 4-azasteroid compound that is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5 alpha-reductase (5AR), intracellular enzymes that convert testosterone to 5 alpha-dihydrotestosterone (DHT). Type I 5a-reductase is predominant in the sebaceous glands of most regions of skin, including scalp, and liver. Type I 5a-reductase is responsible for approximately one-third of circulating DHT. The Type II 5a-reductase isozyme is primarily found in prostate, seminal vesicles, epididymides, and hair follicles as well as liver, and is responsible for two-thirds of circulating DHT.

Mechanism of action

Dutasteride inhibits the conversion of testosterone to 5 alpha-dihydrotestosterone (DHT), which is the androgen primarily responsible for the initial development and subsequent enlargement of the prostate gland. Testosterone is converted to DHT by the enzyme 5 alpha-reductase, which exists as 2 isoforms, type 1 and type 2. Dutasteride is a competitive and specific inhibitor of both type 1 and type 2 5 alpha-reductase isoenzymes, with which it forms a stable enzyme complex. Dissociation from this complex has been evaluated under in vitro and in vivo conditions and is extremely slow. Dutasteride does not bind to the human androgen receptor.

TargetActionsOrganism
A3-oxo-5-alpha-steroid 4-dehydrogenase 2
inhibitor
Human
A3-oxo-5-alpha-steroid 4-dehydrogenase 1
inhibitor
Human
Absorption

60%

Volume of distribution
  • 300 to 500 L
Protein binding

Highly bound to albumin (99%) and α-1 acid glycoprotein (96.6%).

Metabolism

Hepatic. Extensively metabolized by CYP3A4 and CYP3A5 to active metabolites.

Route of elimination

Dutasteride is extensively metabolized in humans. Dutasteride and its metabolites were excreted mainly in feces.

Half life

5 weeks

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
Acetyl sulfisoxazoleThe metabolism of Dutasteride can be decreased when combined with Acetyl sulfisoxazole.
AlbendazoleThe metabolism of Dutasteride can be decreased when combined with Albendazole.
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Dutasteride.
AlfuzosinThe metabolism of Dutasteride can be decreased when combined with Alfuzosin.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Dutasteride.
AmcinonideThe metabolism of Amcinonide can be decreased when combined with Dutasteride.
AmiodaroneThe metabolism of Dutasteride can be decreased when combined with Amiodarone.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Dutasteride.
AmlodipineThe metabolism of Dutasteride can be decreased when combined with Amlodipine.
ApalutamideThe serum concentration of Dutasteride can be decreased when it is combined with Apalutamide.
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Manne Reddy, "Forms of dutasteride and methods for preparation thereof." U.S. Patent US20040077673, issued April 22, 2004.

US20040077673
General References
  1. Keam SJ, Scott LJ: Dutasteride: a review of its use in the management of prostate disorders. Drugs. 2008;68(4):463-85. [PubMed:18318566]
  2. Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL: Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol. 2009 Feb;181(2):621-6. doi: 10.1016/j.juro.2008.10.014. Epub 2008 Dec 16. [PubMed:19091347]
External Links
Human Metabolome Database
HMDB0015258
KEGG Drug
D03820
PubChem Compound
6918296
PubChem Substance
46504830
ChemSpider
5293502
BindingDB
50340481
ChEBI
521033
ChEMBL
CHEMBL1200969
Therapeutic Targets Database
DAP000044
PharmGKB
PA164749300
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Dutasteride
ATC Codes
G04CB02 — DutasterideG04CA52 — Tamsulosin and dutasteride
AHFS Codes
  • 92:08.00 — 5 Alfa Reductase Inhibitors
FDA label
Download (462 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableBenign Prostatic Hyperplasia (BPH)1
1CompletedBasic ScienceAging1
1CompletedBasic ScienceBenign Prostatic Hyperplasia (BPH)1
1CompletedPreventionBenign Prostatic Hyperplasia (BPH)1
1CompletedTreatmentDepression / Healthy Volunteers / Premenstrual Syndrome1
1CompletedTreatmentProstatic Hyperplasia5
1Unknown StatusNot AvailableBenign Prostatic Hyperplasia (BPH) / Healthy Volunteers1
1, 2CompletedTreatmentContraception1
1, 2CompletedTreatmentHealthy Males1
1, 2TerminatedTreatmentProstate Cancer1
2Active Not RecruitingTreatmentErectile Dysfunction (ED) / Lower Urinary Tract Symptoms (LUTS) / Prostate Cancer1
2Active Not RecruitingTreatmentProstate Cancer1
2CompletedTreatmentCancers / Prostate Neoplasms1
2CompletedTreatmentContraception / Hypogonadism1
2CompletedTreatmentKennedy's Disease / Spinal and Bulbar Muscular Atrophy1
2CompletedTreatmentProstate Cancer5
2CompletedTreatmentProstate Cancer After a Radical Treatment / Prostate Neoplasms1
2Not Yet RecruitingTreatmentPituitary gonadotropin hypofunction1
2TerminatedTreatmentProstate Cancer1
2Unknown StatusTreatmentHealthy Volunteers1
2Unknown StatusTreatmentProstate Cancer1
2WithdrawnTreatmentAdenocarcinoma of the Prostate1
2WithdrawnTreatmentLocalized Prostate Cancer / Prostate Cancer1
2, 3CompletedPreventionProstate Cancer1
2, 3CompletedTreatmentHealthy Volunteers1
3CompletedDiagnosticProstate Cancer1
3CompletedPreventionProstate Cancer1
3CompletedPreventionProstate Neoplasms1
3CompletedTreatmentAndrogenetic Alopecia1
3CompletedTreatmentAndrogenetic Alopecia / Hair Thinning1
3CompletedTreatmentBenign Prostatic Hyperplasia (BPH) / Prostatic Hyperplasia1
3CompletedTreatmentHair Thinning2
3CompletedTreatmentProstatic Hyperplasia3
3CompletedTreatmentTranssexualism1
3TerminatedTreatmentBenign Prostatic Hyperplasia (BPH)1
3TerminatedTreatmentBenign Prostatic Hyperplasia (BPH) / Chronic Prostatitis (CP)1
4CompletedTreatmentAlcohol Abuse / Alcohol Dependence / Alcoholism2
4CompletedTreatmentBenign Prostatic Hyperplasia (BPH)2
4CompletedTreatmentBenign Prostatic Hyperplasia (BPH) / Hypogonadism1
4CompletedTreatmentBenign Prostatic Hyperplasia (BPH) / Prostate Cancer1
4CompletedTreatmentBenign Prostatic Hyperplasia (BPH) / Prostatic Hyperplasia1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHypogonadism1
4CompletedTreatmentProstate Cancer1
4CompletedTreatmentProstate Cancer / Prostate Neoplasms1
4CompletedTreatmentProstate Neoplasms1
4TerminatedTreatmentBenign Prostatic Hyperplasia (BPH)1
4TerminatedTreatmentProstatic Hyperplasia1
4Unknown StatusTreatmentBenign Prostatic Hyperplasia (BPH)1
Not AvailableActive Not RecruitingNot AvailableProstate Cancer1
Not AvailableActive Not RecruitingPreventionLow Grade Prostate Cancer / Prostatic Neoplasms1
Not AvailableCompletedNot AvailableAlcohol Abuse / Alcohol Related Disorders / Alcoholism2
Not AvailableCompletedNot AvailableBenign Prostatic Hyperplasia (BPH) / Cancers / Prostate Neoplasms1
Not AvailableCompletedNot AvailableBenign Prostatic Hyperplasia (BPH) / Prostatic Hyperplasia1
Not AvailableCompletedNot AvailableHair Thinning1
Not AvailableCompletedNot AvailableProstate Cancer1
Not AvailableCompletedNot AvailableProstate Neoplasms1
Not AvailableCompletedNot AvailableProstatic Hyperplasia3
Not AvailableCompletedDiagnosticNonmalignant Neoplasm / Prostate Cancer1
Not AvailableCompletedTreatmentBenign Prostatic Hyperplasia (BPH) / Urinary Retention1
Not AvailableCompletedTreatmentBenign Prostatic Hypertrophy (BPH)1
Not AvailableRecruitingTreatmentProstate Cancer1
Not AvailableUnknown StatusTreatmentBMI >30 kg/m2 / Insulin Resistance1
Not AvailableUnknown StatusTreatmentBenign Prostatic Hyperplasia (BPH) / Lower Urinary Tract Symptoms (LUTS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Catalent Pharma Solutions
  • GlaxoSmithKline Inc.
  • Letco Medical Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Resource Optimization and Innovation LLC
  • Santec Chemicals Corp.
Dosage forms
FormRouteStrength
CapsuleOral0.5 mg
Capsule, liquid filledOral0.5 mg/1
CapsuleOral0.5 mg/1
CapsuleOral
Capsule, extended releaseOral
Prices
Unit descriptionCostUnit
Avodart 0.5 mg capsule4.12USD capsule
Avodart 0.5 mg softgel4.06USD softgel capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5846976No1993-09-172013-09-17Us
CA2171329No2004-11-232014-09-16Canada
CA2170047No2004-11-092014-09-16Canada
US5565467No1995-11-202015-11-20Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP6.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000908 mg/mLALOGPS
logP5.45ALOGPS
logP5.79ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)12.56ChemAxon
pKa (Strongest Basic)2.17ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.2 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity127.9 m3·mol-1ChemAxon
Polarizability50.13 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9884
Caco-2 permeable-0.5223
P-glycoprotein substrateSubstrate0.747
P-glycoprotein inhibitor IInhibitor0.7278
P-glycoprotein inhibitor IINon-inhibitor0.6085
Renal organic cation transporterNon-inhibitor0.8299
CYP450 2C9 substrateNon-substrate0.8077
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.7186
CYP450 1A2 substrateNon-inhibitor0.8089
CYP450 2C9 inhibitorInhibitor0.5412
CYP450 2D6 inhibitorNon-inhibitor0.8391
CYP450 2C19 inhibitorInhibitor0.6287
CYP450 3A4 inhibitorNon-inhibitor0.6506
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5913
Ames testNon AMES toxic0.6677
CarcinogenicityNon-carcinogens0.9149
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6885 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9829
hERG inhibition (predictor II)Non-inhibitor0.574
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Androstane steroids
Direct Parent
Androgens and derivatives
Alternative Parents
3-oxo-5-alpha-steroids / 3-oxo-4-azasteroids / 4-azasteroids and derivatives / Trifluoromethylbenzenes / Anilides / N-arylamides / Secondary carboxylic acid amides / Lactams / Azacyclic compounds / Organopnictogen compounds
show 5 more
Substituents
Androgen-skeleton / 3-oxosteroid / 3-oxo-4-azasteroid / 3-oxo-5-alpha-steroid / Oxosteroid / 4-azasteroid / Azasteroid / Trifluoromethylbenzene / Anilide / N-arylamide
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
delta-lactam, aza-steroid, (trifluoromethyl)benzenes (CHEBI:521033)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sterol 5-alpha reductase activity
Specific Function
Converts testosterone (T) into 5-alpha-dihydrotestosterone (DHT) and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation...
Gene Name
SRD5A2
Uniprot ID
P31213
Uniprot Name
3-oxo-5-alpha-steroid 4-dehydrogenase 2
Molecular Weight
28393.015 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Rathnayake D, Sinclair R: Male androgenetic alopecia. Expert Opin Pharmacother. 2010 Jun;11(8):1295-304. doi: 10.1517/14656561003752730. [PubMed:20426708]
  3. Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M: An overview on 5alpha-reductase inhibitors. Steroids. 2010 Feb;75(2):109-53. doi: 10.1016/j.steroids.2009.10.005. Epub 2009 Oct 30. [PubMed:19879888]
  4. Smith AB, Carson CC: Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag. 2009 Jun;5(3):535-45. Epub 2009 Jul 12. [PubMed:19707263]
  5. Goldenberg L, So A, Fleshner N, Rendon R, Drachenberg D, Elhilali M: The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. [PubMed:19543428]
  6. Keam SJ, Scott LJ: Dutasteride: a review of its use in the management of prostate disorders. Drugs. 2008;68(4):463-85. [PubMed:18318566]
  7. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT: Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res. 2006 Jul 1;12(13):4072-9. [PubMed:16818707]
  8. Rittmaster RS, Fleshner NE, Thompson IM: Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol. 2009 May;55(5):1064-73. doi: 10.1016/j.eururo.2009.01.037. Epub 2009 Feb 5. [PubMed:19200641]
  9. Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL: Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol. 2009 Feb;181(2):621-6. doi: 10.1016/j.juro.2008.10.014. Epub 2008 Dec 16. [PubMed:19091347]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Electron carrier activity
Specific Function
Converts testosterone into 5-alpha-dihydrotestosterone and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and andro...
Gene Name
SRD5A1
Uniprot ID
P18405
Uniprot Name
3-oxo-5-alpha-steroid 4-dehydrogenase 1
Molecular Weight
29458.18 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT: Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res. 2006 Jul 1;12(13):4072-9. [PubMed:16818707]
  3. Rathnayake D, Sinclair R: Male androgenetic alopecia. Expert Opin Pharmacother. 2010 Jun;11(8):1295-304. doi: 10.1517/14656561003752730. [PubMed:20426708]
  4. Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M: An overview on 5alpha-reductase inhibitors. Steroids. 2010 Feb;75(2):109-53. doi: 10.1016/j.steroids.2009.10.005. Epub 2009 Oct 30. [PubMed:19879888]
  5. Smith AB, Carson CC: Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag. 2009 Jun;5(3):535-45. Epub 2009 Jul 12. [PubMed:19707263]
  6. Goldenberg L, So A, Fleshner N, Rendon R, Drachenberg D, Elhilali M: The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. [PubMed:19543428]
  7. Keam SJ, Scott LJ: Dutasteride: a review of its use in the management of prostate disorders. Drugs. 2008;68(4):463-85. [PubMed:18318566]
  8. Rittmaster RS, Fleshner NE, Thompson IM: Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol. 2009 May;55(5):1064-73. doi: 10.1016/j.eururo.2009.01.037. Epub 2009 Feb 5. [PubMed:19200641]
  9. Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL: Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol. 2009 Feb;181(2):621-6. doi: 10.1016/j.juro.2008.10.014. Epub 2008 Dec 16. [PubMed:19091347]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on September 23, 2018 19:37